Overview

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED) treatments: carbamazepine/oxcarbazepine, lamotrigine, levetiracetam, or valproic acid in adult subjects with partial-onset seizures (POS) using a flexible dosing regimen.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Anticonvulsants
Ezogabine